DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market - Seite 3

Outlook
The e-prescription is established as the standard in Germany. However, the ramp-up of the prescription medicine business based on the CardLink solution is not yet fully predictable. Against this backdrop, DocMorris confirms the indicative expectations for the 2024 financial year communicated on 21 March:

• an increase in external revenue of more than 10 per cent (including e-prescriptions);
• an improvement in adjusted EBITDA to between CHF 0 million and minus CHF 35 million (including e-prescriptions);
• Capital expenditure of CHF 30 million to CHF 40 million.

In the medium term, an adjusted EBITDA margin of 8 per cent remains the target.

 

Revenue, in CHF million (unaudited)	1.1.-31.3.2024	1.1.-31.3.2023	Change
Continuing operations (excl. Swiss business)
DocMorris external revenue	262.4	248.7	5.5%
DocMorris external revenue in local currency			10.3%
DocMorris	245.9	227.5	8.1%
DocMorris in local currency			13.0%
Markets
Germany external revenue	247.0	232.4	6.3%
Germany external revenue in local currency			11.1%
Germany external revenue Rx	35.5	45.0	-21.1%
Germany external revenue Rx in local currency			-17.5%
Germany external revenue OTC	208.1	185.7	12.0%
Germany external revenue OTC in local currency			17.2%
Germany	230.5	211.2	9.2%
Germany in local currency			14.2%
Europe	15.3	16.3	-6.0%
Europe in local currency			-1.8%